| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | - | 730,000 | 695,000 | - |
| Research and development | 62,931,000 | 54,196,000 | 52,614,000 | - |
| General and administrative | 10,686,000 | 10,391,000 | 10,820,000 | - |
| Total operating expenses | 73,617,000 | 64,587,000 | 63,434,000 | - |
| Operating loss | -73,617,000 | -63,857,000 | -62,739,000 | - |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | - | - | 0 |
| Investment and other income, net | 6,573,000 | 7,257,000 | 8,943,000 | - |
| Net loss | -67,044,000 | -56,600,000 | -53,796,000 | -42,121,000 |
| Unrealized gain on marketable securities | 426,000 | -229,000 | 254,000 | 3,508,000 |
| Comprehensive loss | -66,618,000 | -56,829,000 | -53,542,000 | -38,613,000 |
| Earnings per share, basic | -1.01 | -0.85 | -0.81 | -0.64 |
| Earnings per share, diluted | -1.01 | -0.85 | -0.81 | -0.64 |
| Weighted average number of shares outstanding, basic | 66,420 | 66,392 | 66,383 | 66,294 |
| Weighted average number of shares outstanding, diluted | 66,420 | 66,392 | 66,383 | 66,294 |
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)